Drug Profile


Alternative Names: Combigan; Combigan-D; Timolol/brimonidine

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Allergan
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Morpholines; Propanolamines; Quinoxalines; Thiadiazoles
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 06 Mar 2013 Launched prior to 2013 for Glaucoma in Hong Kong (Ophthalmic)
  • 06 Mar 2013 Launched prior to 2013 for Glaucoma in Malaysia (Ophthalmic)
  • 06 Mar 2013 Launched prior to 2013 for Glaucoma in Mexico (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top